| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERG |
| Uniprot No | P11308 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-479aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHENLYFQGSASTIKEALSVVSEDQSLFECAYG TPHLAKTEMTASSSSDYGQTSKMSPRVPQQDWLSQPPARVTIKMECNPSQ VNGSRNSPDECSVAKGGKMVGSPDTVGMNYGSYMEEKHMPPPNMTTNERR VIVPADPTLWSTDHVRQWLEWAVKEYGLPDVNILLFQNIDGKELCKMTKD DFQRLTPSYNADILLSHLHYLRETPLPHLTSDDVDKALQNSPRLMHARNT GGAAFIFPNTSVYPEATQRITTRPDLPYEPPRRSAWTGHGHPTPQSKAAQ PSPSTVPKTEDQRPQLDPYQILGPTSSRLANPGSGQIQLWQFLLELLSDS SNSSCITWEGTNGEFKMTDPDEVARRWGERKSKPNMNYDKLSRALRYYYD KNIMTKVHGKRYAYKFDFHGIAQALQPHPPESSLYKYPSDLPYMGSYHAH PQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTGGIYPNTRLPTSHMPSH LGTYYLEESGGGGSPGRRRRRRRRRRR |
| 预测分子量 | 59 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ERG重组蛋白的经典文献概览：
1. **《Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer》**
- 作者：Tomlins SA et al. (2005)
- 摘要：首次发现前列腺癌中TMPRSS2与ERG基因的融合现象，揭示了ERG作为ETS家族转录因子在肿瘤发生中的关键作用，为癌症分子机制研究提供新方向。
2. **《The role of ERG in leukemia》**
- 作者：Rainis L et al. (2005)
- 摘要：探讨ERG基因异常表达(如染色体易位导致重组蛋白)与急性淋巴细胞白血病(ALL)的关联，阐明其通过干扰造血分化促进肿瘤生成。
3. **《Structural basis of DNA recognition by the ERG transcription factor》**
- 作者：Donaldson IJ et al. (2012)
- 摘要：解析ERG蛋白的DNA结合结构域，揭示其特异性识别靶基因DNA序列的分子机制，为设计靶向ERG的小分子药物提供结构基础。
4. **《Targeting ERG oncoprotein in therapy-resistant prostate cancer》**
- 作者：Sreenath TL et al. (2019)
- 摘要：研究针对ERG重组蛋白的抑制策略，证明联合抑制ERG和PI3K/AKT通路可克服前列腺癌耐药性，提出潜在治疗靶点。
---
*注：以上文献发表于《Science》《Blood》《Nucleic Acids Research》及《Oncogene》等期刊，聚焦ERG在基因融合、致癌机制及靶向治疗中的应用。建议通过PubMed或期刊官网获取全文。*
**Background of ERG Recombinant Proteins**
The ERG (ETS-related gene) protein, a member of the ETS family of transcription factors, plays critical roles in regulating gene expression during development, cell differentiation, and homeostasis. It binds to DNA via its conserved ETS domain, modulating processes such as angiogenesis, apoptosis, and cell proliferation. ERG is particularly notable for its involvement in endothelial cell function and hematopoietic development.
Recombinant ERG proteins are engineered versions of the native protein, produced using biotechnological systems like *E. coli*, yeast, or mammalian cells. These proteins retain functional domains (e.g., ETS, PNT) and are purified for research or therapeutic applications. Their production often involves tagging (e.g., His-tag) to facilitate isolation and characterization.
Aberrant ERG expression is linked to several cancers. Chromosomal translocations involving the *ERG* gene, such as the *TMPRSS2-ERG* fusion in prostate cancer, result in oncogenic ERG overexpression, driving tumor progression and metastasis. Similar rearrangements are observed in Ewing-like sarcomas and leukemias. Recombinant ERG proteins enable mechanistic studies of these pathologies, helping dissect interactions with cofactors (e.g., FLI1) or DNA targets.
Applications include *in vitro* assays to screen ERG inhibitors, structural studies (e.g., crystallography), and developing diagnostic tools. Additionally, recombinant ERG aids in studying normal biological roles, such as its regulation of vascular development via VEGF signaling. Challenges remain in mimicking post-translational modifications critical for ERG activity, often necessitating mammalian expression systems.
Overall, ERG recombinant proteins serve as vital tools for understanding ERG's dual roles in health and disease, bridging basic research and translational efforts in oncology.
×
